Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells

Anti-Cancer Drugs

Volumn 15, Issue 8, 2004, Pages 787-793

  Treeck, Oliver ^a   Zhou, Rong ^b   Diedrich, Klaus ^c   Ortmann, Olaf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b WEST CHINA UNIVERSITY OF MEDICAL SCIENCES   (China)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Apoptosis; Breast cancer cell line; Drug resistance; Estrogen receptor modulator; Tamoxifen

Indexed keywords

APOPTOSIS INHIBITOR; BETA ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETOPOSIDE; GYRASE INHIBITOR; LIPOCORTIN 5; PROTEIN TYROSINE KINASE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA HISTONE INTERACTION; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANNEXIN A5; APOPTOSIS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETOPOSIDE; GERMANY; HISTONES; HUMANS; HYBRIDIZATION, GENETIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA; STAINING AND LABELING; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 4644243456     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200409000-00008     Document Type: Article

References (37)

1. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1985; 1:16-19.
2. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 2002; 28:165-180.
3. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6:469-477.
4. Farczadi E, Kaszas I, Baki M, Szende B. Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment. Neoplasma 2002; 49:101-103.
5. Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002; 277:45695-45703.
6. Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem 2003; 36:247-253.
7. Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, et al. Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999; 79:257-263.
8. Dietze EC, Caldwell LE, Grupin SL, Mancini M, Seewaldt VL. Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in normal human mammary epithelial cells by inducing mitochondrial depolarization. J Biol Chem 2001; 276:5384-5394.
9. Ahn SJ, Yoon MS, Hyuk S, Han W, Yoon YD, Han JS, et al. Phospholipase C-protein kinase mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. J Cell Biochem 2003; 89:520-528.
10. + tumor cells by upregulating the expression of Fas ligand. Cancer Chemother Pharmacol 2003; 51:284-290.
11. 2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 2000; 60:5995-6000.
12. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, et al. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001; 76:71-84.
13. Johnston SR. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs 1997; 8:911-930.
14. Speirs V, Malone C, Walton DS. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999; 59:5421-5424.
15. Murphy LC, Leygue E, Niu Y. Relationship of coregulator and estrogen receptor isoform expression to tamoxifen resistance in human breast cancer. Br J Cancer 2002; 87:1411-1416.
16. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-9824.
17. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-717.
18. Nicholson RI, Hutcheson IR, Harper ME. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann NY Acad Sci 2002; 963:104-115.
19. Knowlden JM, Hutcheson IR, Jones HE. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032-1044.
20. Houston SJ, Plunkett TA, Barnes DM. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79:1220-1226.
21. Larsen SS, Egeblad M, Jaattela M. Acquired antiestrogen resistance in MCF7 human breast cancer sublines is not accomplished by altered expression of receptors in the erbB-family. Breast Cancer Res Treat 1999; 58:41-56.
22. L, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 1996; 2:1215-1219.
23. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34:1514-1521.
24. Monje P, Boland R. Expression and cellular localization of naturally occurring beta estrogen receptors in uterine and mammary cell lines. J Cell Biochem 2002; 86:136-144.
25. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 1999; 283:543-546.
26. Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993; 364:645-648.
27. Hatzoglou A, Roussel J, Bourgeade MF, Rogier E, Madry C, Inoue J, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000; 165:1322-1330.
28. Gurney AL, Marsters SA, Huang RM, Pitti RM, Mark DT, Baldwin DT, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol 1999; 9:215-218.
29. Miura M, Zhu H, Rotello R, Hartwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993; 75:653-660.
30. Ng PW, Porter AG, Janicke RU. Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10. J Biol Chem 1999; 274:10301-10308.
31. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233-243.
32. Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, et al. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther 2000; 7:1543-1556.
33. Kitada S, Krajewska M, Zhang X, Scudiero D, Zapata JM, Wang HG, et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am J Pathol 1998; 52: 51-61.
34. Wilson JW, Wakeling AE, Morris ID, Hickman JA, Dive C. MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage. Int J Cancer 1995; 61:502-508.
35. Gee JM, Hutcheson IR, Knowlden JM. The EGFR-selective tyrosine kinase inhibitor ZD 1839 ('Iressa') is an effective inhibitor of tamoxifen-resistant breast cancer growth. Proc Am Soc Clin Oncol 2001; 20:282.
36. Brinkman A, van der Flier S, Kok EM, Dorssers LC. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000; 92:112-120.
37. van Agthoven T, van Agthoven TL, Dekker A, van der Spek PJ, Vreede L, Dorssers LC. Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 1998; 17:2799-2808.